Publications by authors named "J Sears"
Article Synopsis
- A study examined long-term opioid prescribing patterns among workers after work-related injuries, focusing on those who had received opioids before their injury.
- The research found that a significant number of workers continued to receive opioids after their injury, especially if they had been prescribed opioids in the three months leading up to the injury.
- Results indicated that 34% of workers with prior opioid prescriptions were still receiving opioids 9-12 months after their injury, compared to only 7% of those without prior use, highlighting the need for healthcare providers to consider a patient’s history with opioids when treating work injuries.
Purpose: To evaluate the clinical outcomes and prognostic factors in unilateral Coats disease in the era of anti-VEGF therapy.
Design: Global, multicenter, retrospective case series.
Subjects: 656 eyes of 656 subjects with Coats disease were included in this study.
RA-0003022 () was identified as a high-quality covalent chemical probe for nsP2 cysteine protease (nsP2pro). Isoxazole covalently captured the active site C478 and inactivated the enzyme with a / ratio of 6000 Ms. A negative control analog RA-0025453 () retained the covalent warhead but demonstrated >100-fold decrease in enzyme inhibition.
View Article and Find Full Text PDFArticle Synopsis
- The study examined children aged 3-18 with low vision at an eye center, focusing on their demographics, surgical history, and health determinants from 2014 to 2019.
- Out of over 47,000 children assessed, 882 had low vision, with common causes including refractive/strabismic amblyopia and retinal diseases; many required surgical interventions.
- Results showed a strong link between the severity of vision loss and the number of surgeries, while no significant relationship was found between patients' income or insurance and their visual outcomes or need for surgery.*
Article Synopsis
- Chikungunya virus (CHIKV) is a mosquito-borne virus causing major outbreaks, with no FDA-approved treatments available.
- Researchers optimized a screening assay for CHIKV's essential protein nsP2 and identified 153 potential drug candidates, including RA-0002034.
- RA-0002034 effectively inhibits CHIKV nsP2 activity and viral replication, making it a promising compound for future therapeutic development against CHIKV and similar viruses.